Investor Presentaiton

CRL Investment Thesis 喘 Kil Unique, scientifically differentiated portfolio with integrated, non- clinical capabilities and broad expertise across all drug modalities Leading partner to accelerate biomedical research and therapeutic innovation with flexible, efficient outsourcing solutions Large and diversified client base across the entire drug research, development, and manufacturing continuum Strong and durable industry fundamentals driven by increased outsourcing to address unmet medical needs and evolving complexity of disease Robust value creation strategy led by M&A and strategic partnerships to maintain leadership positions in high-growth markets Charles River Laboratories (CRL) 5

View entire presentation